CXC chemokine receptor 4 (CXCR4) targeted gold nanoparticles potently enhance radiotherapy outcomes in breast cancer
Open accessThe DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Abstract
CXC chemokine receptor 4 (CXCR4) is overexpressed on most breast cancer cell surfaces including triple negative breast cancer (TNBC) which lacks traditional receptor overexpression.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Gold-based nanoparticles were the most frequently investigated class [20,24,27,28,29], followed by silver-, platinum-, bismuth-, and gadolinium-based platforms [15,30,31,32,33,34,35,36].”
From Nanoparticle-Mediated Radiosensitization in Breast Cancer: A Systematic Review of Preclinical Evidence and Translational Challenges (2026) · cites this paper as [20]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“High-atomic-number (high-Z) nanomaterials were reported to increase local radiation energy deposition through photoelectric interactions, resulting in the generation of secondary electrons and localized dose amplification [15,20,27,28,34].”
From Nanoparticle-Mediated Radiosensitization in Breast Cancer: A Systematic Review of Preclinical Evidence and Translational Challenges (2026) · cites this paper as [20]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“High-atomic-number (high-Z) nanoplatforms based on silver (Z = 47), gadolinium (Z = 64), platinum (Z = 78), gold (Z = 79), and bismuth (Z = 83) enhance radiation-induced energy deposition through photoelectric interactions and secondary electron generation [15,20,27,28,30,33,34,36,50,63].”
From Nanoparticle-Mediated Radiosensitization in Breast Cancer: A Systematic Review of Preclinical Evidence and Translational Challenges (2026) · cites this paper as [20]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“X-ray irradiation was the most frequently reported modality [17,20,27,34,54], whereas megavoltage radiation and radionuclide-based approaches were less commonly used [20,24,61,62].”
From Nanoparticle-Mediated Radiosensitization in Breast Cancer: A Systematic Review of Preclinical Evidence and Translational Challenges (2026) · cites this paper as [20]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Major differences in nanoparticle composition, particle size, surface functionalization, therapeutic payloads, irradiation protocols, experimental models, and outcome assessment methods [15,20,24,33,37,45,52,68,76,81] substantially complicate direct cross-study comparison and limit quantitative synthesis.”
From Nanoparticle-Mediated Radiosensitization in Breast Cancer: A Systematic Review of Preclinical Evidence and Translational Challenges (2026) · cites this paper as [20]
Experimental — accuracy not yet measured
21 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bray, F., Ferlay, J., Soerjomataram, I., Siegel, R. L., Torre, L. A., & Jemal, A. (2018) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21492 · Cited by 84,109
Tensional homeostasis and the malignant phenotype
Paszek, M. J., Zahir, N., Johnson, K. R., Lakins, J. N., Rozenberg, G. I., Gefen, A., Reinhart-King, C. A., Margulies, S. S., Dembo, M., Boettiger, D., et al. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.08.010 · Cited by 3,941
Palma, D. A., Olson, R., Harrow, S., Gaede, S., Louie, A. V., Haasbeek, C., Mulroy, L., Lock, M., Rodrigues, G. B., Yaremko, B. P., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(18)32487-5 · Cited by 1,857
Interactions between cancer stem cells and their niche govern metastatic colonization
Malanchi, I., Santamaria-Martínez, A., Susanto, E., Peng, H., Lehr, H.-A., Delaloye, J.-F., & Huelsken, J. (2012) · Nature · doi:10.1038/nature10694 · Cited by 1,339
Exosomes Mediate Stromal Mobilization of Autocrine Wnt-PCP Signaling in Breast Cancer Cell Migration
Luga, V., Zhang, L., Viloria-Petit, A. M., Ogunjimi, A. A., Inanlou, M. R., Chiu, E., Buchanan, M., Hosein, A. N., Basik, M., & Wrana, J. L. (2012) · Cell · doi:10.1016/j.cell.2012.11.024 · Cited by 1,311
Gold Nanoparticles in Diagnostics and Therapeutics for Human Cancer
Singh, P., Pandit, S., Mokkapati, V. R. S. S., Garg, A., Ravikumar, V., & Mijakovic, I. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19071979 · Cited by 1,038
Self-citationChauhan, V. P., Martin, J. D., Liu, H., Lacorre, D. A., Jain, S. R., Kozin, S. V., Stylianopoulos, T., Mousa, A. S., Han, X., Adstamongkonkul, P., et al. (2013) · Nature Communications · doi:10.1038/ncomms3516 · Cited by 1,031
Breast cancer cells produce tenascin C as a metastatic niche component to colonize the lungs
Oskarsson, T., Acharyya, S., Zhang, X. H.-F., Vanharanta, S., Tavazoie, S. F., Morris, P. G., Downey, R. J., Manova-Todorova, K., Brogi, E., & Massagué, J. (2011) · Nature Medicine · doi:10.1038/nm.2379 · Cited by 869
Lanaspa, M. A., Ishimoto, T., Li, N., Cicerchi, C., Orlicky, D. J., Ruzycki, P., Rivard, C., Inaba, S., Roncal-Jimenez, C. A., Bales, E. S., et al. (2013) · Nature Communications · doi:10.1038/ncomms3929 · Cited by 796
Kucia, M., Reca, R., Miekus, K., Wanzeck, J., Wojakowski, W., Janowska‐Wieczorek, A., Ratajczak, J., & Ratajczak, M. Z. (2005) · STEM CELLS · doi:10.1634/stemcells.2004-0342 · Cited by 759
An improved 2,4,6-trinitrobenzenesulfonic acid method for the determination of amines
Snyder, S. L., & Sobocinski, P. Z. (1975) · Analytical Biochemistry · doi:10.1016/0003-2697(75)90431-5 · Cited by 756
Differences in Breast Cancer Survival by Molecular Subtypes in the United States
Howlader, N., Cronin, K. A., Kurian, A. W., & Andridge, R. (2018) · Cancer Epidemiology, Biomarkers & Prevention · doi:10.1158/1055-9965.epi-17-0627 · Cited by 598
SATAKE, K., OKUYAMA, T., OHASHI, M., & SHINODA, T. (1960) · The Journal of Biochemistry · doi:10.1093/oxfordjournals.jbchem.a127107 · Cited by 484
Chen, I. X., Chauhan, V. P., Posada, J., Ng, M. R., Wu, M. W., Adstamongkonkul, P., Huang, P., Lindeman, N., Langer, R., & Jain, R. K. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1815515116 · Cited by 406
Breast cancer survival by molecular subtype: a population-based analysis of cancer registry data
Fallahpour, S., Navaneelan, T., De, P., & Borgo, A. (2017) · CMAJ Open · doi:10.9778/cmajo.20170030 · Cited by 397
The Role of chemokine receptor CXCR4 in breast cancer metastasis.
Mukherjee, D., & Zhao, J. (2013) · Europe PMC (PubMed Central) · Cited by 297
CXCR4 over-expression and survival in cancer: A system review and meta-analysis
Zhao, H., Guo, L., Zhao, H., Zhao, J., Weng, H., & Zhao, B. (2015) · Oncotarget · doi:10.18632/oncotarget.3217 · Cited by 274
Gold nanoparticles in breast cancer treatment: Promise and potential pitfalls
Lee, J., Chatterjee, D. K., Lee, M. H., & Krishnan, S. (2014) · Cancer Letters · doi:10.1016/j.canlet.2014.02.006 · Cited by 271
Self-citationDewan, M. Z., Ahmed, S., Iwasaki, Y., Ohba, K., Toi, M., & Yamamoto, N. (2006) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2006.06.004 · Cited by 211
CXCR4 in breast cancer: oncogenic role and therapeutic targeting
Yao, Q., Xu, C., Zhao, H., & Chen, H. (2015) · Drug Design, Development and Therapy · doi:10.2147/dddt.s84932 · Cited by 208
Chittasupho, C., Lirdprapamongkol, K., Kewsuwan, P., & Sarisuta, N. (2014) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2014.06.020 · Cited by 103
Chen, G., Chen, S.-M., Wang, X., Ding, X.-F., Ding, J., & Meng, L.-H. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.302299 · Cited by 94
Are breast cancer stem cells the key to resolving clinical issues in breast cancer therapy?
Shima, H., Yamada, A., Ishikawa, T., & Endo, I. (2017) · Gland Surgery · doi:10.21037/gs.2016.08.03 · Cited by 55
Wang, R., Zhi, X., Yao, S., & Zhang, Y. (2015) · Colloids and Surfaces B Biointerfaces · doi:10.1016/j.colsurfb.2015.05.030 · Cited by 52
Using breast cancer cell CXCR4 surface expression to predict liposome binding and cytotoxicity
Guo, P., You, J., Yang, J., Moses, M. A., & Auguste, D. T. (2012) · Biomaterials · doi:10.1016/j.biomaterials.2012.07.043 · Cited by 46
Research works printed but not linked: 2
- Mukherjee, 2013, Am. J. Cancer Res., 3, 46
- Xu, 2015, Drug Des. Devel. Ther., 9, 4953
Cited by
Tian, H., Zhang, T., Qin, S., Huang, Z., Zhou, L., Shi, J., Nice, E. C., Xie, N., Huang, C., & Shen, Z. (2022) · Journal of Hematology & Oncology · doi:10.1186/s13045-022-01320-5 · Cited by 426
Alle, M., Sharma, G., Lee, S. H., & Kim, J. (2022) · Journal of Nanobiotechnology · doi:10.1186/s12951-022-01402-z · Cited by 86
Application of High-Z Nanoparticles to Enhance Current Radiotherapy Treatment
Jackson, N., Cecchi, D., Beckham, W., & Chithrani, D. B. (2024) · Molecules · doi:10.3390/molecules29112438 · Cited by 52
“Bhattarai et al. highlighted the prospect of targeting CXCR4 to enhance the efficacy of GNPs as radiosensitizers [28].”
BackgroundMethodTargeting the chemokine receptor CXCR4 for cancer therapies
Rueda, A., Serna, N., Mangues, R., Villaverde, A., & Unzueta, U. (2025) · Biomarker Research · doi:10.1186/s40364-025-00778-y · Cited by 66
Gupta, N., Mohan, C. D., Shanmugam, M. K., Jung, Y. Y., Chinnathambi, A., Alharbi, S. A., Ashrafizadeh, M., Mahale, M., Bender, A., Kumar, A. P., et al. (2023) · Environmental Research · doi:10.1016/j.envres.2023.116335 · Cited by 37
Metadata
- Authors
- Bhattarai, S., Mackeyev, Y., Venkatesulu, B. P., Krishnan, S., & Singh, P. K.
- Affiliations
- The University of Texas MD Anderson Cancer Center (US)
- Mayo Clinic (US)
- Henry Ford Hospital (US)
- Corresponding author
- Singh, Pankaj K.
- Venue
- Nanoscale
- Publisher
- Royal Society of Chemistry (RSC)
- Published
- 2021
- Volume
- 13
- Issue
- 45
- Pages
- 19056-19065
- ISSN
- 2040-3364 (ISSN-L)
- 2040-3372
- PMC
- PMC9124374
- OpenAlex
- W3205736542
- Cited by
- 22
- References
- 26
- Citations by year
- 2026: 6 · 2025: 5 · 2024: 4 · 2023: 4 · 2022: 3
- FWCI
- 1.79
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Nanoscale (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Cancer Institute (P30 CA16672)
- National Institutes of Health (P30 CA16672)
- Topics
- Physical Sciences › Physics and Astronomy › Radiation › Radiation Therapy and Dosimetry
- Physical Sciences › Engineering › Biomedical Engineering › Nanoplatforms for cancer theranostics
- Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Effects of Radiation Exposure
- Keywords
- CXCR4, gold nanoparticles, targeted radiotherapy, triple-negative breast cancer, radiosensitization, antibody-conjugated nanoparticles, PEGylated nanoparticles, DNA double-strand breaks, oxidative stress, reactive oxygen species, nanoparticle uptake, tumor regrowth, MDA-MB-231 cells
- MeSH terms
- Animals, Breast Neoplasms, Female, Gold, Humans, Receptors, CXCR4, Xenograft Model Antitumor Assays, Cell Line, Tumor, Mice, Metal Nanoparticles, Triple Negative Breast Neoplasms
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.